Abstracts

Rationale: Clobazam is a novel 1, 5 benzodiazepine approved by the US food and drug administration (FDA) in October 2011 for the treatment of seizures. Clobazam, first approved in Australia in 1970 and in France in 1974. Adverse effects are reported in 8 to 50 % of patients depending on the studies, but only a total 4 % of patients had to be withdrawn from controlled or open label studies on account of side effects. Clobazam had been used in our center for the past 15 years and it is essential to evaluate its tolerability and adverse effects in the patients treated.  Methods: Retrospective chart review of 180 patients treated with Clobazam as an add on therapy for intractable epilepsy. Data were collected and entered into red cap (data base).The following information were collected age, gender, seizure type ,seizure frequency/month, reported side effects and rate of Clobazam discontinuation.  Results: 180 patients were reviewed, age 0.16-21 years, mean age 9.8 years, females 76,males 104.Total of 7 out of 180 (3.8%) patients experienced adverse effects. The side effects reported (table 1). 10 out of 180 (5.5) patients stopped the medication, the reasons for Clobazam discontinuation (table 2).   Conclusions: Clobazam side effects in our population is low 3.8%.Discontinuation of Clobazam is quite low 5.5%.Clobazam is a well-tolerated anticonvulsant with low rate of side effects.  Funding: no funding